Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Johnson & Johnson : J&J Cancer Drug Zytiga Now Backed For Publicly Funded Use In UK

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/16/2012 | 11:11am CET

The U.K.'s health-care cost-effectiveness regulator Wednesday reversed an earlier decision and approved the publicly funded use of Johnson & Johnson's (JNJ) prostate-cancer pill Zytiga, after the U.S. company cut its price further.

Also known as abiraterone, Zytiga removes the prostate cancer tumor's supply of testosterone, preventing it from growing further and potentially extending a patient's life by more than three months. The medicine was rejected for use in the U.K. in February on grounds its terms of use wouldn't offer value for money.

Andrew Dillon, chief executive of the U.K.'s National Institute for Health and Clinical Excellence, or NICE, Wednesday said the manufacturer subsequently submitted fresh information, including a revised patient access scheme containing a deeper price discount to the National Health Service and more information about which patients would most benefit from its use and how many patients could receive the drug.

"These factors enabled the committee to revise its preliminary recommendation and now recommend the drug for use on the NHS," Dillon said in a statement. "It is an effective treatment, potentially extending life by more than three months, and it also allows patients to be treated at home as it can be taken orally."

Abiraterone costs GBP2,930 for a 30-day supply of 120 tablets. NICE didn't specify the size of the price cut offered by Johnson & Johnson.

Zytiga was approved by U.S. and European drug regulators last year. It is set to generate peak-year sales of $910 million.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
10:47p JOHNSON & JOHNSON : Tech firm seeks $3.3 in tax credits; plans move to R.I.
04:20p JOHNSON & JOHNSON : Wants to Tap Innovators Worldwide to Help Create the Healthi..
03/21 JOHNSON & JOHNSON : Ministry of Health launches Diabetes Early Detection Program..
03/21 JOHNSON & JOHNSON : to Host Investor Conference Call on First-Quarter Results
03/21 JOHNSON & JOHNSON : Global Dental Anesthesia Market Key Players Astra Zeneca, Se..
03/18 JOHNSON & JOHNSON : New Phase 3 Study Finds XARELTO® to Be Superior to Aspirin f..
03/18 JOHNSON & JOHNSON : New Phase 3 Study Finds XARELTO to Be Superior to Aspirin fo..
03/17 JOHNSON & JOHNSON : University of Leicester - Leicester Precision Medicine Insti..
03/17 JOHNSON & JOHNSON : opens regional offices in Ghana and Kenya
03/16 TALCUM POWDER LAWSUIT NEWS : FDA Funds Research to Investigate Ovarian Cancer Ri..
More news
Sector news : Pharmaceuticals - NEC
09:14p MYLAN : recalls 81,000 EpiPens outside U.S. after reports of failure
03/21DJSANOFI'S PRESCRIPTION FOR GROWTH : Drug Sales in the Middle Kingdom
03/20 FTSE rises to record close after Article 50 trigger date set
03/17DJPFIZER : Files 8K - Other Events
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01:14p Wells Fargo sees significant upside in Xarelto sales if use expanded to CV ri..
12:41p WORD ON WALL STREET : Pharma Segment Key To Johnson & Johnson's 2017 Performance
11:42a JOHNSON & JOHNSON : Great Business With A Great Future - A Great Time To Buy?
10:31a 5 Dividend Stocks Expected To Increase Distributions In 2017
08:27a MY 4% DIVIDEND YIELD PORTFOLIO : Q1'17 Summary And Short Term Expectations
Advertisement
Financials ($)
Sales 2017 74 629 M
EBIT 2017 23 135 M
Net income 2017 18 205 M
Finance 2017 22 716 M
Yield 2017 2,63%
P/E ratio 2017 19,11
P/E ratio 2018 17,87
EV / Sales 2017 4,32x
EV / Sales 2018 4,07x
Capitalization 344 961 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 126 $
Spread / Average Target -1,2%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON10.45%344 961
ROCHE HOLDING LTD.8.81%216 473
PFIZER INC.5.45%203 963
NOVARTIS AG2.09%195 883
MERCK & CO., INC.8.56%175 469
SANOFI7.59%115 573
More Results